Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 2, 2013, Pages 327-332

  Toldi, Gergely ^a,b   Beko, Gabriella ^a   Kádár, Gabriella ^c   MácSai, Emília ^d   Kovács, László ^c   Vásárhelyi, Barna ^a,b   Balog, Attila ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d Csolnoky Hospital   (Hungary)

Author keywords

C reactive protein (CRP); erythrocyte sedimentation rate (ESR); inflammation; rheumatoid arthritis; soluble urokinase plasminogen activator receptor (suPAR)

Indexed keywords

C REACTIVE PROTEIN; SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84875417519     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0221     Document Type: Article

References (17)

1. Danoø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8:189-203.
2. Behrendt N, Stephens RW. The urokinase receptor. Fibrinolysis Proteol 1998;12:191-204.
3. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoøyer-Hansen G, Roønne E, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1876-84.
4. Roønne E, Pappot H, Groøndahl-Hansen J, Hoøyer-Hansen G, Plesner T, Hansen NE, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995;89:576-81.
5. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004;36:14-9.
6. Ostrowski SR, Ullum H, Goka BQ, Hoøyer-Hansen G, Obeng Adjei G, Pedersen BK, et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005;191:1331-41.
7. Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol 2001;8:1196-203.
8. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-9.
9. Toldi G, Bíró E, Szalay B, Stenczer B, Molvarec A, Rigó J Jr, et al. Soluble urokinase Plasminogen Activator Receptor (suPAR) levels in healthy pregnancy and preeclampsia. Clin Chem Lab Med 2011;49:1873-6.
10. Thunoø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009;27:157-72.
11. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
12. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
13. [No authors listed] ICSH recommendations for measurement of erythrocyte sedimentation rate. International Council for Standardization in Haematology (Expert Panel on Blood Rheology) J Clin Pathol 1993;46:198-203.
14. Slot O, Brünner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999;58:488-92.
15. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999;79:717-22.
16. Riisbro R, Christensen IJ, Hoøgdall C, Brünner N, Hoøgdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001;16:233-9.
17. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011;63:3702-11.